Efficacy of Short Hydration for Intermediate to High-Dose Cisplatin-Based Chemotherapy for Outpatient
Phase 2
Active, not recruiting
- Conditions
- cancer patients who treated with intermediate to high dose cisplatin in outpatient.Short hydrationcisplatinNephrotoxicitychemoprevention
- Registration Number
- TCTR20210128002
- Lead Sponsor
- Division of Medical Oncology, Department of Internal Medicine, Buddhasothorn Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 13
Inclusion Criteria
1.cancer patients who treated with intermediate to high dose cisplatin in outpatient
2.age > 18 year
3.ECOG performance status 0-2
4. adequate renal function eGFR>60 mL/min
Exclusion Criteria
1. underlying heart disease ,poor LV function
2.eGFR decline >20% from baseline after cisplatin administration
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method nephrotoxicity week 3, week6,week9,week12, week 15 after enroll eGFR
- Secondary Outcome Measures
Name Time Method /A N/A N/A